Data from a recent study suggest that it is possible for some patients to be cured of uterine cervical neoplasms. It is important, therefore, that the patient be informed about the likelihood of achieving cure.
The current study showed that vaginal ultrasound screening was not appropriate as a method to detect cervical neoplasms at an early stage. However, the results may play some role in the prevention of cervical cancer and uterine cervical neoplasms.
Symptoms of uterine cervical neoplasms do not occur immediately. However, patients with uterine endometrial hyperplasia or cancer often complain of nonmenstrual irregularities of the rectum.
While less than 10% of all women will have uterine cervical neoplasms, approximately 30% to 35% of women will have a high risk. Women aged 25 to 54 yr at the highest risk for uterine cervical neoplasms, and women aged less than 30 yr are also at higher risk for uterine cervical neoplasms compared with other women. The incidence and frequency of many different uterine cervical neoplasms in the U.S. are declining and not declining at the same rate as the incidence between the 1970s and the 2000s. These declines are a result of decreasing use of high-dose estrogen and use of hormonal contraceptives.
The leading factors influencing women with cervical neoplasms were age above 48years and parity number > or =2. The increased rate of cervical neoplasms in females was likely due to the HPV16. The uterine malignant neoplasms were mostly of squamous cell carcinoma type, which has close correlation with a history of tobacco smoking.
There are no specific treatments for uterine cervical neoplasms. Regular clinical follow-up by a hygroscopic provider is an important treatment for uterine cervical neoplasms. Patients with uterine cervical neoplasms should undergo monthly gynecologic evaluations to help rule out cancer, especially dysplasia. If necessary, surgical excision, hysterectomy, and pelvic exenteration may be the final modality.
Survival rate for uterine cervical neoplasms is variable and depends primarily on disease location and histologic type. Overall, mortality for uterine cervical neoplasms is low. Survival rates for women of European ancestry are better than those of African Americans or Hispanics.
Nearly one quarter of neoplasms were diagnosed in the younger age group while only 1 of 9 neoplasms were diagnosed in the older age group. The trend of increased disease in the younger age group was not reversed in the older age group.
Although a number of novel therapies have recently been developed, none of them have yet appeared to be clinically helpful in treating uterine cervical neoplasms.
Uterine cervical neoplasms were the fifth-most common malignancy among women in Norway in the year 2007, with an estimated incidence rate of 1,907 cases per 100,000 women in the age group of 30-64 years. The leading subgroups of disease (squamous cell or adenocarcinoma) were comparable with results obtained in previous Norwegian studies, and this country appears to have excellent results (4.1% death rates among treated patients and 0.7% recurrences in the 5 years after treatment).
This article highlights recent developments in investigational use of pembrolizumab for therapeutic use. Also, this article discusses what clinicians should look for, including response time, toxicity, and clinical activity in women with solid uterine tumors.
In a recent study, findings, the efficacy and safety profile of pembrolizumab for uterine cervical cancer patients with high-risk papillary serous carcinoma is consistent with that of previous published open-label studies. Further study with more comprehensive assessments of efficacy and safety is warranted.